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Abnormal chromosome number, or aneuploidy, is a common feature of human solid tumors, including oral cancer. Deregulated
spindle assembly checkpoint (SAC) is thought as one of the mechanisms that drive aneuploidy. In normal cells, SAC prevents
anaphase onset until all chromosomes are correctly aligned at the metaphase plate thereby ensuring genomic stability. Significantly,
the activity of this checkpoint is compromised in many cancers. While mutations are rather rare, many tumors show altered
expression levels of SAC components. Genomic alterations such as aneuploidy indicate a high risk of oral cancer and cancer-related
mortality, and the molecular basis of these alterations is largely unknown. Yet, our knowledge on the status of SAC components
in oral cancer remains sparse. In this review, we address the state of our knowledge regarding the SAC defects and the underlying
molecular mechanisms in oral cancer, and discuss their therapeutic relevance, focusing our analysis on the core components of
SAC and its target Cdc20.
1. Introduction
Oral cancer is amongst the most commonmalignancy affect-
ing mainly individuals with a history of tobacco and alcohol
abuse [1]. Significantly, overall oral cancer-related mortality
remained unchanged over the past two decades [2] despite
significant improvement in quality of life thanks to advances
in surgical techniques, radiotherapy, and chemotherapy.
Thus, a major challenge in oral cancer diagnosis and treat-
ment is to identify new therapeutic targets.
Contrary to microsatellite instability (MIN) which is
rather rare, chromosomal instability (CIN) is the most fre-
quent form of genetic instability in oral cancer, with frequent
gains and losses of whole chromosomes or chromosomal
segments [3]. CIN status in oral cancer was associated
with a poor prognosis [3, 4]. Therefore, understanding the
molecular mechanisms that underlie CIN is relevant to the
clinic as it may lead to new anticancer therapy or to the
discovery of new and more accurate prognostic markers that
help guide therapeutic choices.
A number of reports demonstrated that alterations in
the spindle assembly checkpoint (SAC) components can
generate aneuploidy and induce tumor formation in animal
models [5–7]. The SAC is a highly conserved surveillance
mechanism that functions during mitosis to ensure accurate
chromosome distribution between the two daughter cells
[8, 9]. At the onset of mitosis, SAC proteins assemble on
unattached kinetochores to produce an inhibitory signal that
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prevents the onset of anaphase until all chromosomes became
bipolarly attached to microtubules of the mitotic spindle. It
is thus expectable that alterations in SAC protein levels will
produce abnormal chromosome segregation thus generating
aneuploidy.
Given the unstable karyotype found in oral cancer cells
and the role that SAChas in the generation of aneuploidy, this
review aimed at presenting the state of our knowledge on SAC
dysfunctions in oral cancer and discussing its therapeutic
potential.
2. Oral Cancer
Oral cancer constitutes a major health problem being the
sixth most common human cancer worldwide, with an inci-
dence of more than 300,000 cases annually, with variations
between countries and geographical areas [10]. In Southeast
Asia, oral cancer shows the highest incidence and prevalence
due to influence of tobacco and betel quid chewing habits
[11]. High-risk human papilloma viruses (HR-HPVs) and
Epstein-Barr virus (EBV) have also been identified as increas-
ingly important risk factors [12–16]. Within the spectrum
of oral malignancies, almost 90 percent are squamous cell
carcinomas (SCC) [17]. Despite advances in knowledge on
prevention and treatment of oral cancer, a low survival rate
(near 50%) has been observed during the last decades [2,
18]. This is probably related to the late diagnosis, at a time
when cancer has already metastasized. Indeed, patients have
a better prognosis if they are treated in early stages, with
a 5-year survival rate as high as 80% [12, 19, 20]. Suitable
markers to early detect oral cancer and also to differentiate
patients with more risk for recurrence or disease progression
are therefore urgently needed [21].
Several genetic alterations including mutations, ampli-
fications, translocations, or methylations have been impli-
cated in oral cancer progression, affecting several tumor
suppressors such as TP53 and RB and oncogenes like cyclins,
EGFR, and ras [11, 22].Through these alterations, tumor cells
acquire autonomous growth and evade growth-inhibitory
signals, leading to uncontrolled tumor growth. Mutations
in TP53 gene are the most common genetic alterations,
affecting around 45% of oral carcinomas [23, 24] and are
associated with smoking [10]. These mutations affect DNA
repair and compromise DNA damage-induced apoptosis,
resulting in further genetic abnormalities and malignancy
[10]. Expression of upstream regulators of pRb function, such
as TP16, is also commonly altered [25] and may be involved
in early stages of oral tumorigenesis [26]. In addition to
overexpression of the ras oncogene family, which is linked
to malignant transformation [27], EGFR, the receptor of
EGF and TGF-𝛼, is also commonly overexpressed in oral
cancers. EGFR overexpression is linked to differentiation and
aggressiveness of the tumors [26]. Also, overexpression of
Cyclin D1 is frequent and is associated with recurrence and
nodal metastasis [23].
Despite the advances in our understanding of the molec-
ular basis of oral carcinogenesis and of oral cancer therapy,
detailed information on the mechanisms that drive stepwise
tumor progression is still missing. Such informationmay help
uncover new biomarkers and develop potential therapeutic
targets.
A common hallmark of several human cancers, includ-
ing oral cancer, is aneuploidy, mainly defined as abnormal
number of chromosomes.Mechanistically, chromosomemis-
segregation due to abnormal mitosis is thought as one of the
driving forces toward aneuploidy. Accurate chromosome seg-
regation during mitosis is monitored by the spindle assembly
checkpoint, a signaling pathway that inhibits anaphase onset
until all chromosomes are aligned at the metaphase equator
[28]. Defects in this checkpoint are common inmany cancers
and are associated with aneuploidy generation and tumor
progression.
3. Spindle Assembly Checkpoint
Error-free chromosome segregation depends on the success-
ful attachment of chromosomes, through its sister kineto-
chores, to microtubules from the mitotic spindle [29]. By
monitoring the nature of kinetochore-microtubules interac-
tions, the spindle assembly checkpoint (SAC), a surveillance
and error-sensitive mechanism, avoids a premature sister-
chromatid separation and ensures genomic stability [8]. The
key signal for SAC activation is the presence of unattached
or improperly attached kinetochores, which acts as a cat-
alytic platform for the assembly of the mitotic checkpoint
complex (MCC), an inhibitory signal of the metaphase
to anaphase transition. The MCC comprises the highly
conserved proteins Mad2, BubR1, and Bub3 in association
with Cdc20 protein, a coactivator of the E3 ubiquitin lig-
ase anaphase promoting complex/cyclosome (APC/C) [30].
Once this complex is generated, Cdc20 is unable to activate
the APC/C, preventing anaphase onset by inhibiting Securin
and Cyclin B degradation by ubiquitin/proteasome system
(Figure 1(a)). A single free-kinetochore is able to activate
the SAC transduction pathway and sustain a mitotic arrest
[31]. This is possible because the inhibitory signal that
emanates from the unattached kinetochore diffuses into and
is further amplified within the cytoplasm. Such diffusion
and amplification of the inhibitory signal are based on
catalytic conformational conversion of Mad2 protein. At
unattached kinetochores, the binary complex Mad1-“closed”
Mad2 acts as a scaffold for a continuous conversion of
the cytosolic “open” Mad2 into “closed” Mad2, which is
able to bind Cdc20 and inhibit APC/C activity [32–35].
Recently, it was reported that a “closed” Mad2-dependent
Cdc20 conformational change allows the binding of Cdc20
with the N terminus of BubR1 bound to Bub3, which in
turn inhibits the APC/C activity and consequently anaphase
onset (Figure 1(b)) [36]. Additional SAC components include
the kinases Bub1, monopolar spindle 1 (Mps1), and Aurora
B which are required for effective checkpoint signaling.
Bub1, which forms a constitutive complex with Bub3 [37], is
required for kinetochore recruitment of BubR1, Mad1, and
Mad2 [38]. This kinase also contributes to APC/C inhibition
through Cdc20-phosphorylation [39, 40]. In vertebrate cells,
kinetochore targeting ofMad1 andMad2 is also dependent on





















































Figure 1: Current models of the signaling pathway of the spindle assembly checkpoint (SAC). (a) According to the first model, the presence
of unattached or inappropriate attached kinetochores activates the SAC (SAC on). At the kinetochore level, the complexMad1-“closed” Mad2
generates a diffusible signal, converting the cytosolic “Open” Mad2 into new “Closed” Mad2, which in association with Bub3, BubR1, and
Cdc20 forms the mitotic checkpoint complex. Mitotic checkpoint complex (MCC) sequesters Cdc20 preventing activation of the anaphase
promoting complex/cyclosome (APC/C). Once all chromosomes are properly attached, MCC disassembles (SAC off) and Cdc20 is free to
activate the APC/C that targets Securin and Cyclin B for degradation. This way, Separase is released and cleaves Coesins allowing sister
chromatid separation, while Cyclin B degradation allows mitosis exit. (b) According to the second model, cytosolic “closed” Mad2 promotes
a conformational change in Cdc20, allowing its binding to the N terminus of BubR1 bound to Bub3, which maintain the APC/C inhibited
thus preventing anaphase onset. Once this complex is formed, “closed” Mad2 is released and returns to cytosol.
Mps1 which in turn is required for Aurora B kinase activation
[41–44]. Aurora B is a component of chromosomal passenger
complex (CPC), which also includes INCENP, Survivin, and
Borealin, and has a role in correcting aberrant kinetochore-
microtubule attachments [45]. In a process that involves
substrate phosphorylation, Aurora B senses and destabilizes
improper kinetochore-microtubule attachments, giving a
second chance for successful chromosomes biorientation and
alignment, thereby avoiding an aneuploid end [9, 46, 47].
Besides its role in error-correction, Aurora B also plays an
important role in BubR1 and Mad2 kinetochore recruit-
ment [48]. Once all chromosomes align at the metaphase
plate, with proper bipolar attachments, the “wait anaphase”
inhibitory signal must be extinguished, a process known as
SAC silencing, to allow mitosis progression. A predominant
mechanism of SAC silencing implies disassembly of existing
MCC and preventing assembly of newMCC [49]. OnceMCC
is extinguished, Cdc20 becomes free to activate the APC/C
which targets Securin and Cyclin B for degradation, thus
leading to sister-chromatid separation and mitotic exit.
4. Spindle Assembly Checkpoint
and Aneuploidy
Theodor Boveri has suggested that aneuploid progeny, result-
ing from disrupted mitosis, becomes the precursor cells
of tumors [50]. In fact, nowadays it is well known that
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aneuploidy is a common feature of solid human tumors and
is a contributor factor in tumorigenesis [28]. In order to
maintain the same karyotype, every cell cycle, the cell must
ensure that each daughter cell only receives one copy of
each chromosome. Since this process is controlled by SAC,
a compromised SAC will result in aneuploid cells, with too
many or too few chromosomes, a state that contributes to
carcinogenesis [51]. Actually, there are evidences that a weak
mitotic checkpoint correlates with an increase in aneuploid
cells. Although impaired, thisweak SAC is not null, as cells are
able to divide and survive. However, the gain or loss of whole
chromosomes is frequent in these cells, ultimately leading
to aneuploidy [50]. Chromosome gain or loss is known as
chromosomal instability (CIN), the basis of aneuploidy and
cancer. In fact, most cancer cells exhibit CIN and, frequently,
high rate of aneuploidy and CIN is correlated with a poor
patient prognosis [52, 53].
From a therapeutic point of view, chronic spindle assem-
bly checkpoint activation is commonly used in chemotherapy
and relies on the use of microtubule-targeting agents, which
by disrupting microtubule dynamics elicits a long-term SAC
response that frequently ends inmitotic cell death [54]. How-
ever, some cells are able to escape cell death and exit mitosis,
a mechanism coined mitotic slippage [55]. Cell fate after
SAC-dependent mitotic arrest induced by antimicrotubule
drugs was suggested to be determined by two independent
processes that run in parallel: (i) if the apoptotic machinery
is efficiently activated, during the mitotic arrest, before
Cyclin B reaches a threshold of degradation, then the cell is
committed to die; (ii) if the threshold of Cyclin B degradation
is reached before efficient activation of apoptosis, then the
cell will exit without dying in mitosis [56]. Paradoxically,
complete SAC inactivation also results in cell death. This
potential anticancer strategy relies on the fact that, without
a functional SAC, CIN is increased to a rate that produces
massivemissegregations resulting in unviable progeny. Taken
together, this suggests that a careful fine-tuning of SAC
activity is required for cell survival, since aweakened SAC can
favor tumorigenesis but the absence or chronic activation of
SAC results in apoptosis, even in tumor cells [52].
5. Spindle Assembly Checkpoint and Oral
Squamous Cell Carcinoma
Oral squamous cell carcinoma (OSCC), like most other
cancers, exhibits aneuploid cells. This carcinoma is char-
acterized by complex karyotypes, often near-triploid, and
contains multiple structural and numeric genetic abnormal-
ities [57]. As stated above, defects in SAC are amongst the
causes of aneuploidy in various cancers. As for oral cancer,
there are only few reports that described SAC alterations
in OSCC (Table 1). Overexpression of Cdc20, at mRNA
levels, was reported in both OSCC-derived cell lines and
primary head and neck squamous cell carcinoma (HNSCC)
tissues [58]. Cell lines overexpressingCdc20 undergomitosis,
with decreased Cyclin B levels, even in the presence of the
microtubule disruption drug nocodazole, demonstrating an
impairment of SAC function [58]. Cdc20 overexpression was
also observed in OSCC-derived cell lines with p53 and p16
defects [59]. The same study reported Mad2 downregulation
in OSCC cell lines, which may account for the complex kary-
otypes in these cells [58]. Interestingly, downregulated Mad2
and BubR1 increased sensitivity of esophageal squamous cell
carcinoma lines to antimicrotubule agents currently used
in chemotherapy, highlighting the predictive value of these
SAC proteins for anticancer drug sensitivity [60]. Recently,
Cdc20 overexpression in OSCC histological samples was
linked to a poor prognosis, suggesting Cdc20 as a novel
independent prognostic factor, as well as a molecular marker
to categorize high-risk OSCC subgroups [61]. BubR1 was
found to be overexpressed in OSCC samples and, in less
extent, in oral potentially malignant disorders, comparatively
to normal oral mucosa, suggesting that BubR1 upregulation
is an early event in oral carcinogenesis pathway [62]. High
BubR1 expression was associated with shorter survival in
oral malignant lesions and, interestingly, a possible corre-
lation between HPV infection and BubR1 overexpression
was suggested [63]. In contrast, another study shows that
overexpression of BubR1 was associated with a less advanced
tumor stage, but patients with overexpression of BubR1
showed shorter recurrence-free survival than those without
it, making BubR1 a promising prognostic marker in patients
with OSCC [64]. Curiously, the proliferation marker Ki-
67 did not demonstrate a statistical significant correlation
with BubR1 expression, contrasting with a previous report in
patients with tonsillar carcinomas [65]. Another SAC protein
that was also found to be overexpressed in oral carcinoma is
the Aurora B kinase. A positive correlation between the clin-
icopathological parameters, disease-free survival and Aurora
B expression, was reported, suggesting that Aurora B status
might be useful to identify the risk patients and can be used
as a potential prognostic factor [66]. Aurora B was involved
in lymph node metastatic process and poor differentiation
grade. Together with its colocalization pattern with Ki-67, a
role of Aurora B in tumor progression was suggested [67].
Recently, overexpression of Aurora B was associated with
advanced tumor stage and a poor prognosis of OSCCpatients
[68], strengthening the potential of Aurora B status as an
OSCC predictive biomarker [66]. Overall, the overexpression
patterns of Cdc20, BubR1, and Aurora B proteins in OSCC
(Table 1) are similar to those observed in other tumor types
[69–71].
We have focused our analysis on core SAC components
(Mad1, Mad2, Bub1, BubR1, Bub3, Aurora B, and Mps1) as
well as on the main target of SAC (Cdc20). As described
above and summarized in Table 1, little information exists
as to the expression status of SAC proteins in oral cancer
comparatively to other cancers. Overall expression status of
Mad2, BubR1, Aurora B, and Cdc20 in oral cancer seems con-
cordant between different reports, with a general tendency to
upregulation, except forMad2. However, there is no report as
to the expression status of the other aforementioned core SAC
proteins. This missing information is crucial as SAC activity,
and the significance of its alteration to cancer, depends on
the fine-tuned equilibrium between all of its components and
their expression levels.
BioMed Research International 5
Table 1: Expression levels of core spindle assembly checkpoint components in oral squamous cell carcinoma.
SAC protein Samples Expression levels References
Cdc20
OSCC cell lines (7 out of 10)
Primary HNSCC (7 out of 10 cases) Overexpression [58]
OSCC cell lines (2 of 7) Overexpression [59]
OSCC (37 out of 65 cases) Overexpression [61]
Mad2 OSCC cell lines (7 out of 7) Underexpression [59]
BubR1
OSCC (43 out of 43 cases)
Oral PMD (75 out of 77 cases) Overexpression [62]
OSCCIS (15 out of 20 cases)
OSCCWT (19 out of 27 cases)
OSCCW (18 out of 23 cases)
Cervical LN (15 out of 23 cases)
Overexpression [63]
OLNM (16 out of 16 cases) Underexpression
OSCC (11 out of 49 cases) Overexpression [64]
Aurora B
OSCC cell lines (7 out of 7)
OSCC (71 out of 101) Overexpression [66]
OSCC (40 out of 40 cases) Overexpression [67]
OSCC (162 out of 215 cases) Overexpression [68]
PMD: potentially malignant disorders; OSCCIS: in situOSCC; OSCCWT: invasive OSCCwithout metastasis; OSCCW: invasive OSCC with metastasis; cervical
LN: lymph nodes; OLNM: nonmalignant oral lesions.
6. Conclusion
The SAC is compromised in many malignant tumors and has
been implicated as a contributor to aneuploidy and carcino-
genesis in animals and human. Over- and underexpression
of SAC components were reported in various types of cancer.
In many cases, the SAC component expression status is
linked with a high proliferation activity and a poor prognosis.
Consequently, targeting the SAC pathway for anticancer
therapies has been investigated [72] and some drugs are
currently in various stages of clinical trials. For instance,
Aurora B kinase inhibitors induce apoptosis in vitro and in
vivo and are being tested in clinical trials [73–75]. However,
and as it can be concluded from this review, there is still a lack
of knowledge on the status of SAC components in oral cancer.
Extending our understanding of the expression profile to all
SAC components, and to other components participating in
the SAC, may be useful to oral cancer treatment. Eventually,
this would help determine whether oral cancer patients can
potentially benefit from anti-SAC agents that are currently in
active clinical development.
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